ALV-100

Phase 1Small molecule

AAlveus Therapeutics, Inc.

ALV-100 is one of 2 small molecule programs targeting Overweight or Obese. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overweight or ObeseRecruiting

Overweight or ObesePhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Overweight or Obese

#DrugCompanyPhaseTrials

BGM0504

BBrightGene Bio-Medical Technology Co., Ltd.

Phase 2

1 2

ALV-100

AAlveus Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Overweight or Obese

NCT07399678

Clinical

Trials by Indication[1]

Overweight or Obese1 trial

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALV-100 in Participants With Overweight or Obesity With or Without Type 2 Diabetes

Recruiting·AAlveus Therapeutics, Inc.·Phase 1·NCT07399678·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALV-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALV-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALV-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alveus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAlveus Therapeutics, Inc.

ALV-100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Overweight or Obese1 trial

References

Drug Info

Quick Facts

Related News